Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
German pharmaceutical company Stada Arzneimittel has acquired a portfolio of products from Takeda for $660 million.
The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.
Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.
Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.
The National Committee on IP Rights of the Philippines prevented more than PHP455 million worth of counterfeit medicines and personal care products from reaching consumers in the first seven months of this year.
The US House Committee on Energy & Commerce has voted to advance a drug pricing plan which would lower the cost of many prescription drugs.
Actavis Laboratories cannot market a generic version of Horizon Pharma’s knee pain treatment, an appeals court has ruled.
Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.
California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.